Organometallic ruthenium complexes with triphenylphosphane amino acid bioconjugates as possible anticancer compounds (CROSBI ID 641376)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa
Podaci o odgovornosti
Pernar, Margareta ; Kokan, Zoran ; Matković, Marija ; Piantanida, Ivo ; Polančec, Denis ; Turel, Iztok ; Kirin, Srećko I. ; Brozović, Anamaria
engleski
Organometallic ruthenium complexes with triphenylphosphane amino acid bioconjugates as possible anticancer compounds
Cytotoxic activity of newly synthesized (p-cymene)-ruthenium complexes 1 and 2, bearing phosphane ligands substituted with chiral or non-chiral amino acid esters was investigated on human cervix carcinoma cell line (HeLa) using MTT assay. Four (2pG, 2pA, 2mG and 2mA) out of six synthesized metallated biconjugates showed significant toxicity, with IC50 values of 5 to 30 μM. 2mG compound with average value of IC50 16 μM was selected for further biological characterisation. The higher level of toxicity towards tumour compared to normal cell lines indicates its selective activity, important characteristic for potential medical use. Further, it was detected that 2mG causes dose- and time-dependent increase of SubG1 cell population, suggesting its ability to induce apoptosis and stop cells in G1/S phase of cell cycle. Moreover, the role of glutathione in HeLa cells response to investigated organometallic ruthenium complexes was confirmed by using specific regulators of GSH synthesis, buthionine sulfoximine and N-acetyl-cysteine. Pre-treatment of cells with ethacrynic acid and probenecid emphasizes role of GSH in detoxification of 2mG compound. We speculate that ruthenium complexes bind protein-based biomolecules triggering further cell death. Based on the gained knowledge, the synthesis and development of more tumour-specific ruthenium-based complexes as potential anticancer drugs is expected.
cancer ; organometallic ruthenium complexes ; cell death ; triphenylphosphane amino acid bioconjugates ; anticancer compounds
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
47-47.
2016.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Libri oncologici : Croatian journal of oncology
Zagreb:
0300-8142
2584-3826
Podaci o skupu
HDIR-4 "From Bench to Clinic", Fourth Meeting of the Croatian Association for Cancer Research with International Participation
poster
03.11.2016-04.11.2016
Zagreb, Hrvatska